Imbria Pharmaceuticals announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase II study of the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy.
[Imbria Pharmaceuticals]
7992332
{7992332:nan}
apa
50
1
164718
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
